Cubist Systematic Strategies’s Charles River Laboratories CRL Stock Holding History

Cubist Systematic Strategies’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$2.85M	Sell	18,200 -3,700	-17%	-$588K	0.01%	1335
2025 Q2	$3.32M	Buy	21,900 +18,400	+526%	+$2.45M	0.02%	1273
2025 Q1	$527K	Sell	3,500 -200	-5%	-$33.5K	﹤0.01%	2142
2024 Q4	$683K	Hold	3,700	–	–	﹤0.01%	2028
2024 Q3	$729K	Buy	+3,700	New	+$769K	﹤0.01%	2016
2023 Q4	–	Sell	-2,200	Closed	-$431K	–	3673
2023 Q3	$431K	Hold	2,200	–	–	﹤0.01%	2399
2023 Q2	$463K	Buy	2,200 +1,000	+83%	+$199K	﹤0.01%	2435
2023 Q1	$242K	Buy	+1,200	New	+$272K	﹤0.01%	3116

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cubist Systematic Strategies's CRL Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of Charles River Laboratories (CRL) in Q3 2025, closing a stake of 77,065 shares — an estimated $12.2M sold.

Cubist Systematic Strategies first reported a position in CRL in Q2 2014 and held it in 37 quarters. The position peaked at $15.8M in Q1 2022. 555 funds tracked by Wall St. Rank hold CRL as of Q3 2025.

Cubist Systematic Strategies reported no remaining Charles River Laboratories position as of Q3 2025 after selling out during the quarter.
Cubist Systematic Strategies sold 77,065 Charles River Laboratories shares in Q3 2025, an estimated $12.2M.
Cubist Systematic Strategies first reported a position in Charles River Laboratories in Q2 2014 and held it in 37 quarters.
Cubist Systematic Strategies's Charles River Laboratories position peaked at $15.8M in Q1 2022.
555 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.